Systemic antifungal therapy for tinea capitis in children

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Chen, Xiaomei ^a   Jiang, Xia ^a   Yang, Ming ^a   González, Urbà ^b   Lin, Xiufang ^a   Hua, Xia ^a   Xue, Siliang ^a   Zhang, Min ^a   Bennett, Cathy ^c  

^a SICHUAN UNIVERSITY   (China)

^b Unit of Dermatology   (Spain)

^c Faculty of Engineering and Computing   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE; NAPHTHALENE DERIVATIVE;

CINAHL; DATA BASE; DERMATOPHYTE; DRUG EFFICACY; DRUG INDUSTRY; EMBASE; FOLLOW UP; HUMAN; IMMUNITY; LOW DRUG DOSE; MEDLINE; MICROSCOPY; MICROSPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; RISK; SYSTEMATIC REVIEW; TINEA CAPITIS; TREATMENT DURATION; TRICHOPHYTOSIS; UNSPECIFIED SIDE EFFECT; CHILD; META ANALYSIS;

ANTIFUNGAL AGENTS; CHILD; FLUCONAZOLE; GRISEOFULVIN; HUMANS; ITRACONAZOLE; KETOCONAZOLE; NAPHTHALENES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TINEA CAPITIS;

EID: 84966715276     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004685.pub3     Document Type: Review

References (69)

1. Cáceres-Ríos H, Rueda M, Ballona R, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. Journal of the American Academy of Dermatology 2000;42(1 Pt 1):80-4. [MEDLINE: 10607324]
2. Cáceres-Ríos H, Rueda M, Ballona R, Mostajo F, Kumakawa H, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. [Abstract 015]. Annales de Dermatologie et de Venereologie 1998;125(Suppl 1):1s21.
3. Dastghaib L, Azizzadeh M, Jafari P. Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. Journal of Dermatological Treatment 2005;16(1):43-6. [MEDLINE: 15897167]
4. Deng S, Hu H, Abliz P, Wan Z, Wang A, Cheng W, et al. A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China. Mycopathologia 2011;172(5):365-72. [MEDLINE: 21701791]
5. Elewski BE, Caceres HW, DeLeon L, El Shimy S, Hunter JA, Korotkiy N, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. Journal of the American Academy of Dermatology 2008;59(1):41-54. [MEDLINE: 18378354]
6. Foster KW, Friedlander SF, Panzer H, Ghannoum MA, Elewski BE. A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. Journal of the American Academy of Dermatology 2005;53(5):798-809. [MEDLINE: 16243128]
7. Friedlander SF, Aly R, Krafchik B, Blumer J, Honig P, Stewart D, et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics 2002;109(4):602-7. [MEDLINE: 11927703]
8. Fuller LC, Smith CH, Cerio R, Marsden RA, Midgley G, Beard AL, et al. A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. British Journal of Dermatology 2001;144(2):321-7. [MEDLINE: 11251566]
9. Gan VN, Petruska M, Ginsburg CM. Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin. Pediatric Infectious Disease Journal 1987;6(1):46-9. [MEDLINE: 3822616]
10. Gupta AK, Adam P, Dlova N, Lynde CW, Hofstader S, Morar N, et al. Therapeutic options for the treatment of tinea capitis caused by trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatric Dermatology 2001;18(5):433-8. [MEDLINE: 11737692]
11. Hamm H, Schwinn A, Bräutigam M, Weidinger G. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. The Study Group. British Journal of Dermatology 1999;140(3):480-2. [MEDLINE: 10233270]
12. Schwinn A, Hamm H, Bräutigam M, Weidinger G, Williams T. What is the best approach to tinea capitis with terbinafine? [Abstract P147]. Annales de Dermatologie et de Venereologie 1998;125(Suppl 1):1s133-1s134.
13. Schwinn A, Hamm H, Bräutigam M, Weidinger G, Williams T. What is the best approach to tinea capitis with terbinafine? [Abstract P199]. The 7th Congress of the European Academy of Dermatology and Venereology; 7-11 Oct 1998; Nice. Journal of the European Academy of Dermatology & Venereology 1998;11(Suppl 2):s232.
14. Alvi KH, Iqbal N, Khan KA, Haroon TS, Hussain I, Aman S, et al. A randomized, double blind trial of the efficacy and tolerability of terbinafine once daily compared to griseofulvin once daily in the treatment of tinea capitis. In: Shuster S, Jafary MH editor(s). Royal Society of Medicine Services International Congress Series. Vol. 205, London: Royal Society of Medicine Press Ltd, 1992:35-40.
15. Haroon TS, Hussain I, Aman S, Jahangir M, Kazmi AH, Sami AR, et al. Randomized double-blind multicentre study of efficacy and tolerability of terbinafine for 1, 2, and 4 weeks in the treatment of tinea capitis. Journal of the European Academy of Dermatology & Venereology 1995;5(Suppl 1):s79-s80.
16. Haroon TS, Hussain I, Aman S, Nagi AH, Ahmad I, Zahid M, et al. A randomized double-blind comparative study of terbinafine and griseofulvin in tinea capitis. Journal of Dermatological Treatment 1995;6(3):167-9. [DOI: 10.3109/09546639509097176; EMBASE: 1995319728]
17. Haroon TS, Hussain I, Aman S, Jahangir M, Kazmi AH, Sami AR, et al. A randomized double-blind comparative study of terbinafine for 1, 2, and 4 weeks in tinea capitis. British Journal of Dermatology 1996;135(1):86-8. [MEDLINE: 8776365]
18. Jahangir M, Hussain I, Ul Hassan M, Haroon TS. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. British Journal of Dermatology 1998;139(4):672-4. [MEDLINE: 9892912]
19. Khan SU, Khan AR, Wazir SM. Efficacy of terbinafine vs. griseofulvin in tinea capitis in the northern areas of Pakistan. Journal of Pakistan Association of Dermatologists 2011;21(4):281-4.
20. Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of terbinafine in the treatment of tinea capitis. Journal of the American Academy of Dermatology 1997;37(2 Pt 1):272-3. Comment in Journal of the American Academy of Dermatology 1998; 39(1):136. [MEDLINE: 9270519]
21. Lipozencic J, Skerlev M, Orofino-Costa R, Zaitz VC, Horvath A, Chouela E, et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. British Journal of Dermatology 2002;146(5):816-23. [MEDLINE: 12000378]
22. López-Gómez S, Del Palacio A, Van Cutsem J, Soledad Cuétara M, Iglesias L, Ródriguez-Noriega A. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. International Journal of Dermatology 1994;33(10):743-7. Comment in the International Journal of Dermatology 1994;33(10):701. [MEDLINE: 8002149]
23. Martínez-Roig A, Torres-Rodríguez JM, Bartlett-Coma A. Double blind study of ketoconazole and griseofulvin in dermatophytoses. The Pediatric Infectious Disease Journal 1988;7(1):37-40. [MEDLINE: 3277154]
24. Memisoglu HR, Erboz S, Akkaya S, Akan T, Aksungur VL, Ünal I, et al. Comparative study of the efficacy and tolerability of 4 weeks of terbinafine therapy with 8 weeks of griseofulvin therapy in children with tinea capitis. Journal of Dermatological Treatment 1999;10(3):189-93. [DOI: 10.3109/09546639909056027]
25. Rademaker M, Havill S. Griseofulvin and terbinafine in the treatment of tinea capitis in children. New Zealand Medical Journal 1998;111(1060):55-7. [MEDLINE: 9539918]
26. Solomon BA, Collins R, Sharma R, Silverberg N, Jain AR, Sedgh J, et al. Fluconazole for the treatment of tinea capitis in children. Journal of the American Academy of Dermatology 1997;37(2 Pt 1):274-5. [MEDLINE: 9270520]
27. Filho ST, Cucé LC, Foss NT, Marques SA, Santamaria JR. Efficacy, safety and tolerability of terbinafine for tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1, 2 and 4 weeks. Journal of the European Academy of Dermatology & Venereology 1998;11(2):141-6. [MEDLINE: 9784040]
28. Tanz RR, Stagl S, Esterly NB. Comparison of ketoconazole and griseofulvin for treatment of tinea capitis in childhood: a preliminary study. Pediatric Emergency Care 1985;1(1):16-8. [MEDLINE: 3916457]
29. Tanz RR, Hebert AA, Esterly NB. Treating tinea capitis: Should ketoconazole replace griseofulvin?. Journal of Pedriatics 1988;112(6):987-91. [MEDLINE: 3373408]
30. Ungpakorn R, Ayutyanont T, Reangchainam S, Supanya S. Treatment of Microsporum spp. tinea capitis with pulsed oral terbinafine. Clinical and Experimental Dermatology 2004;29(3):300-3. [MEDLINE: 15115516]
31. Ginsburg C, Ghan NV, Petruska M. Randomized controlled trial of intralesional corticosteroid and griseofulvin vs. griseofulvin alone for treatment of kerion. The Pediatric Infectious Disease Journal 1987;6(12):1084-7. [MEDLINE: 3324039]
32. Honig PJ, Caputo GL, Leyden JJ, McGinley K, Selbst SM, McGravey AR. Treatment of kerions. Pediatric Dermatology 1994;11(1):69-71. [MEDLINE: 8170855]
33. Hussain I, Muzaffar F, Rashid T, Ahmad TJ, Jahangir M, Haroon TS. A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs. griseofulvin alone. Medical Mycology 1999;37(2):97-9. [MEDLINE: 10361264]
34. Koumantaki-Mathioudaki E, Devliotou-Panagiotidou D, Rallis E, Athanassopoulou V, Koussidou-Eremondi T, Katsambas A, et al. Is itraconazole the treatment of choice in Microsporum canis tinea capitis?. Drugs Under Experimental & Clinical Research 2005;31(Suppl):11-5. [MEDLINE: 16444907]
35. Shemer A, Plotnik IB, Davidovici B, Grunwald MH, Magun R, Amichai B. Treatment of tinea capitis - griseofulvin versus fluconazole - a comparative study. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology] 2013;11(8):737-41. [MEDLINE: 23575220]
36. Pather S. A prospective, randomized, single-blinded trial to determine the efficacy of single and weekly dose regimens of oral griseofulvin versus 6 weeks of daily dosing in the treatment of tinea capitis in children. British Society for Paediatric Dermatology: Summaries of Papers [PA-6]. British Journal of Dermatology 2006;155(Suppl 1):108-109. [DOI: 10.1111/j.1365-2133.2006.07258_1.x]
37. Abdel-Rahman SM, Herron J, Fallon-Friedlander S, Hauffe S, Horowitz A, Riviere GJ. Pharmacokinetics of terbinafine in young children treated for tinea capitis. Pediatric Infectious Disease Journal 2005;24:886-91.
38. Aly R. Ecology, epidemiology and diagnosis of tinea capitis. The Pediatric Infectious Diseases Journal 1999;18(2):180-5. [MEDLINE: 10048699]
39. Aste N, Pau M. Tinea capitis caused by Microsporum canis treated with terbinafine. Mycoses 2004;47(9-10):428-30. [MEDLINE: 15504128]
40. Bennassar A, Grimalt R. Management of tinea capitis in childhood. Clinical, Cosmetic & Investigational Dermatology: CCID 2010;3:89-98.
41. Bennett ML, Fleischer AB, Loveless JW, Feldman SR. Oral griseofulvin remains the treatment of choice for tinea capitis in children. Pediatric Dermatology 2000;17(4):304-9. [MEDLINE: 10990583]
42. Blumer JL. Pharmacologic basis for the treatment of tinea capitis. The Pediatric Infectious Disease Journal 1999;18(2):191-9. [MEDLINE: 10048701]
43. Bortolussi R, Martin S, Canadian Paediatric Society. Antifungal agents for common outpatient paediatric infections. http://www.cps.ca/documents/position/antifungal-agents-common-infections (accessed 26 February 2016).
44. Chan YC, Friedlander SF. Therapeutic options in the treatment of tinea capitis. Expert Opinion on Pharmacotherapy 2004;5(2):219-27. [MEDLINE: 14996619]
45. Commens C. Which drug is most effective in treating childhood tinea capitis caused by Microsporum species?. The Medical Journal of Australia 2003;178(11):577-8. [MEDLINE: 12765508]
46. Devliotou-Panagiotidou D, Koussidou-Eremondi TH. Efficacy and tolerability of 8 weeks' treatment with terbinafine in children with tinea capitis caused by Microsporum canis: a comparison of three doses. Journal of the European Academy of Dermatology & Venereology 2004;18(2):155-9. [MEDLINE: 15009293]
47. Elewski BE. Tinea capitis: a current perspective. Journal of the American Academy of Dermatology 2000;42(1 Pt 1):1-24. [MEDLINE: 10607315]
48. Fleece D, Gaughan JP, Aronoff SC. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials. Pediatrics 2004;114(5):1312-5. [MEDLINE: 15520113]
49. Friedlander SF. The optimal therapy for tinea capitis. Pediatric Dermatology 2000;17(4):325-6. [MEDLINE: 10990588]
50. Fuller LC, Child FJ, Midgley G, Higgins EM. Diagnosis and management of scalp ringworm. BMJ 2003;326(7388):539-41. [MEDLINE: 12623917]
51. Fuller LC, Barton RC, Mohd Mustapa MF, Proudfoot LE, Punjabi SP, Higgins EM. British Association of Dermatologists' guidelines for the management of tinea capitis 2014. Br J Dermatol 2014;171:454-63.
52. Ginter-Hanselmayer G, Weger W, Ilkit M, Smolle J. Epidemiology of tinea capitis in Europe: current state and changing patterns. Mycoses 2007;50(Suppl 2):6-13. [MEDLINE: 17681048]
53. Gupta AK, Hofstader SLR, Adam P. Tinea capitis: an overview with emphasis on management. Pediatric Dermatology 1999;16(3):171-89. [MEDLINE: 10383772]
54. Gupta AK, Cooper EA, Bowen JE. Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis. Journal of Drugs in Dermatology 2008;7(4):369-72. [PUBMED: 18459518]
55. Gupta AK, Drummond-Main C. Meta-analysis of randomized, controlled trials comparing particular doses of griseofulvin and terbinafine for the treatment of tinea capitis. Pediatric Dermatology 2013;30(1):1-6. [PUBMED: 22994156]
56. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008;51(Suppl 4):2-15. [DOI: 10.1111/j.1439-0507.2008.01606.x; MEDLINE: 18783559]
57. Hay R, Bendeck SE, Chen S, Estrada R, Haddix A, McLeod T, et al. Chapter 37 Skin Diseases. In: Jamison DT, Breman JG, Measham AR, et al. editor(s). Disease Control Priorities in Developing Countries. 2nd Edition. Washington (DC): World Bank, 2006:online. [www.ncbi.nlm.nih.gov/books/NBK11733/]
58. Higgins EM, Fuller LC, Smith CH. Guidelines for the management of tinea capitis. British Journal of Dermatology 2000;143(1):53-8. [MEDLINE: 10886135]
59. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
60. Kakourou T, Uksal U, European Society for Pediatric Dermatology. Guidelines for the management of tinea capitis in children. Pediatric Dermatology 2010;27(3):226-8. [PUBMED: 20609140]
61. Lewis James H, Zimmerman HYMAN J, Benson Gordon D, Ishak Kamal G. Hepatic injury associated with ketoconazole therapy. Analysis of 1984;33:503-13.
62. Pomeranz AJ, Sabnis SS, McGrath GJ, Esterly NB. Asymptomatic dermatophyte carriers in the households of children with tinea capitis. Archives of Pediatrics & Adolescent Medicine 1999;153(5):483-6. [MEDLINE: 10323628]
63. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
64. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. [DOI: 10.1136/bmj.c332]
65. Schünemann H, Brozek J, Guyatt G, Oxman A (editors). GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations [updated October 2013]. gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html (accessed 23 March 2016). [Available from guidelinedevelopment.org/handbook.]
66. Tey HL, Tan AS, Chan YC. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. Journal of the American Academy of Dermatology 2011;64(4):663-70. [PUBMED: 21334096]
67. Yu J, Li R, Bulmer G. Current topics of tinea capitis in China. Japanese Journal of Medical Mycology 2005;46(2):61-6. [MEDLINE: 15864248]
68. Zonios DI, Bennett JE. Update on azole antifungals. Seminars in Respiratory and Critical Care Medicine 2008;29:198-210.
69. Gonzalez U, Seaton T, Bergus G, Jacobson J, Martinez-Monzon C. Systemic antifungal therapy for tinea capitis in children. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD004685.pub2]